Equity Profile

CTMX

CytomX Therapeutics, Inc.

Health CareBiotechnology$734.3M

Aug6Thu

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

CytomX Therapeutics, Inc. is a biotechnology company focused on developing innovative cancer therapies....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth signals the company's ability to expand its market presence and product offerings, crucial for investor confidence.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

CTMX Q2-2026 Earnings Preview

Context

Company Snapshot

CytomX Therapeutics, Inc. is a biotechnology company focused on developing innovative cancer therapies. With a market cap of $1 billion, it operates in the health care sector, aiming to create targeted treatments that can improve patient outcomes in oncology.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

63%

Avg EPS Surprise

+61.67%

Avg Stock Reaction

+21.44%

Last Quarter Recap

In Q1-2026, CytomX reported an EPS of -$0.10, outperforming analyst expectations by 29.58%. However, the stock declined by 3.15% the next day, indicating mixed investor sentiment.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, expectations for CytomX's upcoming earnings are uncertain due to the lack of analyst estimates and management guidance. Investors are likely looking for signs of revenue growth and improved EPS.

Bull Case

If CytomX can demonstrate significant progress in its clinical trials or partnerships, it could lead to a positive market reaction and increased investor confidence.

Bear Case

Conversely, if the company fails to show progress or reports worse-than-expected financials, it could lead to a sharp decline in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the expected revenue growth for CytomX's pipeline products?

Revenue growth will be a key indicator of the company's market traction and future potential, influencing investor sentiment.

How does CytomX plan to address the recent EPS performance?

Management's strategy to improve EPS will be crucial for restoring investor confidence and driving stock performance.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate CytomX's potential for revenue growth due to its innovative pipeline, which could yield unexpected results.

Supporting Evidence

The options market is pricing in a 37.5% move, suggesting significant uncertainty that may not align with actual performance.

CytomX has a history of surprising the market with better-than-expected EPS, which could happen again this quarter.

Key Risk

If revenue growth exceeds expectations, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether CytomX can turn around its financial performance and show growth in its product pipeline.

Bull Confirmed If

A revenue growth rate exceeding 20% would confirm the bullish case.

Bear Confirmed If

If EPS remains below -$0.10, it would support the bearish outlook.

Pre-Earnings Positioning

Options Market

Implied Move

±37.5%

Historical Avg

±23.1%

Pricing rich

The options market is pricing in a significant potential price movement, reflecting uncertainty around the earnings report.

Options are pricing ±37.5% while CTMX has averaged ±23.1% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.9%

30d HV

37.6%

Calls (36K)P/C Ratio: 0.03Puts (100)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If CytomX beats expectations, history suggests the stock could rise around 25.20%, confirming a positive outlook.

In-Line / Cautious

An in-line report may lead to muted reactions, as investors await clearer guidance on future growth.

Miss

If the company misses expectations, history indicates a potential decline of about 15.16%, raising concerns about its financial health.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on clinical trial results for key products.
2Any new partnerships or collaborations that could impact revenue.
3Management's outlook on future product launches.
4Details on cost management strategies to improve EPS.
5Insights into market demand for CytomX's therapies.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Danaos Corporation

Company Snapshot

CytomX Therapeutics, Inc. is a biotechnology company focused on developing innovative cancer therapies....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth signals the company's ability to expand its market presence and product offerings, crucial for investor confidence.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

CTMX Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

63%

Avg EPS Surprise

+61.67%

Avg Stock Reaction

+21.44%

Last Quarter Recap

In Q1-2026, CytomX reported an EPS of -$0.10, outperforming analyst expectations by 29.58%. However, the stock declined by 3.15% the next day, indicating mixed investor sentiment.

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If CytomX can demonstrate significant progress in its clinical trials or partnerships, it could lead to a positive market reaction and increased investor confidence.

Bear Case

Conversely, if the company fails to show progress or reports worse-than-expected financials, it could lead to a sharp decline in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the expected revenue growth for CytomX's pipeline products?

Revenue growth will be a key indicator of the company's market traction and future potential, influencing investor sentiment.

How does CytomX plan to address the recent EPS performance?

Management's strategy to improve EPS will be crucial for restoring investor confidence and driving stock performance.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate CytomX's potential for revenue growth due to its innovative pipeline, which could yield unexpected results.

Supporting Evidence

The options market is pricing in a 37.5% move, suggesting significant uncertainty that may not align with actual performance.

CytomX has a history of surprising the market with better-than-expected EPS, which could happen again this quarter.

Key Risk

If revenue growth exceeds expectations, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether CytomX can turn around its financial performance and show growth in its product pipeline.

Bull Confirmed If

A revenue growth rate exceeding 20% would confirm the bullish case.

Bear Confirmed If

If EPS remains below -$0.10, it would support the bearish outlook.

Pre-Earnings Positioning

Options Market

Implied Move

±37.5%

Historical Avg

±23.1%

Pricing rich

The options market is pricing in a significant potential price movement, reflecting uncertainty around the earnings report.

Options are pricing ±37.5% while CTMX has averaged ±23.1% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.9%

30d HV

37.6%

Calls (36K)P/C Ratio: 0.03Puts (100)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If CytomX beats expectations, history suggests the stock could rise around 25.20%, confirming a positive outlook.

In-Line / Cautious

An in-line report may lead to muted reactions, as investors await clearer guidance on future growth.

Miss

If the company misses expectations, history indicates a potential decline of about 15.16%, raising concerns about its financial health.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on clinical trial results for key products.
2Any new partnerships or collaborations that could impact revenue.
3Management's outlook on future product launches.
4Details on cost management strategies to improve EPS.
5Insights into market demand for CytomX's therapies.